Hypertriglyceridemia-induced acute pancreatitis (HTG-AP) is associated with a high risk of recurrence despite standard lipid-lowering therapy and lifestyle modification. The goal of this clinical trial is to evaluate whether GLP-1 receptor agonist therapy can reduce the recurrence of HTG-AP in adults with a history of HTG-AP and hypertriglyceridemia.
The main questions this study aims to answer are:
* Whether GLP-1 receptor agonist therapy reduces the recurrence rate of HTG-AP.
* Whether GLP-1 receptor agonist therapy improves triglyceride control, body weight, and metabolic parameters.
* Whether GLP-1 receptor agonist therapy is safe and well tolerated in this patient population.
Researchers will compare GLP-1 receptor agonist therapy plus standard care with standard care alone to determine whether GLP-1 receptor agonist therapy provides additional benefit in preventing recurrent HTG-AP.
Participants will:
* Receive either GLP-1 receptor agonist therapy plus standard care or standard care alone.
* Undergo regular clinical follow-up visits and laboratory assessments.
* Receive monitoring of triglyceride levels, recurrence events, metabolic outcomes, and adverse events during the study period.